Keywords
hypertension, metabolic syndrome, myocardial hypertrophy, ramipril, hydrochlorothiazide, treatment.
How to Cite
Zhuravlyova, L., & Ilchenko, I. (2014). The influence of fixed combination of ramipril and hydrochlorothiazide on the daily profile of blood pressure and the regression of myocardial hypertrophy in hypertensive patients with metabolic disorders. The Practitioner, (3), 39-44. Retrieved from https://plr.com.ua/index.php/journal/article/view/327
Abstract
The article presents the results of a 6-month treatment with a fixed combination of 10 mg of ramipril and 12.5 mg of hydrochlorothiazide in patients with moderate hypertension and metabolic disorders. These results demonstrate the effect of treatment on the daily profile and variability of blood pressure, regression of left ventricular hypertrophy, improvement of diastolic function, as well as metabolic neutrality.
References
1. Гипертрофия миокарда левого желудочка у пациентов с метаболическим синдромом и ее регресс под действием квинаприла / Е.И. Митченко,
В.Ю. Романов, Г.Б. Каспрук, Т.В. Беляева // Кардиология. – 2007. – №4. – С. 14-19.
2. Моисеев В.С. Эффекты рамиприла в лечении и профилактике заболеваний сердечно-сосудистой системы и почек / В.С. Моисеев // Клиническая
фармакология и терапия. – 2005. – №5. – С. 52-58.
3. Преображенский Д.В. Рамиприл – ингибитор ангиотензин-превращающего фермента с широким спектром терапевтического действия / Д.В. Пре-
ображенский, И.Д. Вышинская // Справочник поликлинического врача. – 2010. – №2. – С. 15-20.
4. Рязанов А.С. Клинико-генетические аспекты развития гипертрофии миокарда левого желудочка / А.С. Рязанов // Российский кардиологический
журнал. – 2003. – №2. – С. 21-29.
5. Шевченко О.П. Ингибиторы АПФ у больных метаболическим синдромом / О.П. Шевченко, А.О. Шевченко // Кардиология. – 2012. – №4. – С. 42-46.
6. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND
(Trial on Reversing Endothelial Dysfunction) Study / B.G.M. Mancini, G.C. Henry, C. Macay [et al.] // Circulation. – 1996. – Vol. 94. – P. 258-265.
7. Cardiac structure and function in the obese: a cardiovascular magnetic resonance imaging study / P.G. Danias, N.A. Tritos, M. Stuber [et al.] // J. Cardiovasc.
Magn. Reson. – 2003. – Vol. 5. – P. 431-438.
8. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis / P. Verdecchia, F. Angeli, C. Borgioni [et al.] // Am. J.
Hypertens. – 2003. – Vol. 16. – P. 11-32.
9. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension / M. Clozel // Hypertension. – 2012. – Vol. 18. – P. 37-42.
10. Comparative study of four antihypertensive agents on endothelial function in patients with coronary disease / T.J. Anderson, R.W. Overhiser, H. Haber, F.A. Charbonneau
// J. Am. Coll. Cardiol. – 2012. – Vol. 31, Suppl. A. – P. 327A.
11. Devereux R.В. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method / R.В. Devereux, N. Reichek // Circulation.
– 1977. – Vol. 55. – P. 613-618.
12. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // N. Engl. J. Med. – 2000. – Vol. 342. – Р. 145-153.
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy //
Lancet. – 2000. – Vol. 355. – Р. 253-259.
14. Gillis C.N. Lisinopril and ramiprilat protection of the vascular endothelium against free radical induced functional injury / C.N. Gillis, X. Chen, M.M. Merker //
J. Pharmacol. Exp. Ther. – 1992. – Vol. 262. – P. 212-216.
15. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans / G. Bonner, S. Preis, U. Schunck [et al.] //
J. Cardiovasc. Pharmacol. – 2011. – Vol. 15, Suppl. 6. – P. 46-56.
В.Ю. Романов, Г.Б. Каспрук, Т.В. Беляева // Кардиология. – 2007. – №4. – С. 14-19.
2. Моисеев В.С. Эффекты рамиприла в лечении и профилактике заболеваний сердечно-сосудистой системы и почек / В.С. Моисеев // Клиническая
фармакология и терапия. – 2005. – №5. – С. 52-58.
3. Преображенский Д.В. Рамиприл – ингибитор ангиотензин-превращающего фермента с широким спектром терапевтического действия / Д.В. Пре-
ображенский, И.Д. Вышинская // Справочник поликлинического врача. – 2010. – №2. – С. 15-20.
4. Рязанов А.С. Клинико-генетические аспекты развития гипертрофии миокарда левого желудочка / А.С. Рязанов // Российский кардиологический
журнал. – 2003. – №2. – С. 21-29.
5. Шевченко О.П. Ингибиторы АПФ у больных метаболическим синдромом / О.П. Шевченко, А.О. Шевченко // Кардиология. – 2012. – №4. – С. 42-46.
6. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND
(Trial on Reversing Endothelial Dysfunction) Study / B.G.M. Mancini, G.C. Henry, C. Macay [et al.] // Circulation. – 1996. – Vol. 94. – P. 258-265.
7. Cardiac structure and function in the obese: a cardiovascular magnetic resonance imaging study / P.G. Danias, N.A. Tritos, M. Stuber [et al.] // J. Cardiovasc.
Magn. Reson. – 2003. – Vol. 5. – P. 431-438.
8. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis / P. Verdecchia, F. Angeli, C. Borgioni [et al.] // Am. J.
Hypertens. – 2003. – Vol. 16. – P. 11-32.
9. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension / M. Clozel // Hypertension. – 2012. – Vol. 18. – P. 37-42.
10. Comparative study of four antihypertensive agents on endothelial function in patients with coronary disease / T.J. Anderson, R.W. Overhiser, H. Haber, F.A. Charbonneau
// J. Am. Coll. Cardiol. – 2012. – Vol. 31, Suppl. A. – P. 327A.
11. Devereux R.В. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method / R.В. Devereux, N. Reichek // Circulation.
– 1977. – Vol. 55. – P. 613-618.
12. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // N. Engl. J. Med. – 2000. – Vol. 342. – Р. 145-153.
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy //
Lancet. – 2000. – Vol. 355. – Р. 253-259.
14. Gillis C.N. Lisinopril and ramiprilat protection of the vascular endothelium against free radical induced functional injury / C.N. Gillis, X. Chen, M.M. Merker //
J. Pharmacol. Exp. Ther. – 1992. – Vol. 262. – P. 212-216.
15. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans / G. Bonner, S. Preis, U. Schunck [et al.] //
J. Cardiovasc. Pharmacol. – 2011. – Vol. 15, Suppl. 6. – P. 46-56.
Downloads
Download data is not yet available.